TELO Earnings Telomir Pharmaceuticals, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–14 of 14
| Q1 2026 | 2026-03-31 | -0.03 | 2026-05-14 | 10-Q |
| FY 2025 | 2025-12-31 | -0.33 | 2026-03-17 | 10-K |
| Q3 2025 | 2025-09-30 | -0.27 | 2025-11-10 | 10-Q |
| Q2 2025 | 2025-06-30 | 0.24 | 2025-08-14 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.07 | 2026-05-14 | 10-Q |
| FY 2025 | 2024-12-31 | -0.56 | 2026-03-17 | 10-K |
| Q3 2025 | 2024-09-30 | -0.46 | 2025-11-10 | 10-Q |
| Q2 2025 | 2024-06-30 | 0.26 | 2025-08-14 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.23 | 2025-05-14 | 10-Q |
| FY 2024 | 2023-12-31 | 0.48 | 2025-02-04 | 10-K |
| Q3 2024 | 2023-09-30 | -0.14 | 2024-11-12 | 10-Q |
| Q2 2024 | 2023-06-30 | -0.08 | 2024-08-13 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.02 | 2024-05-13 | 10-Q |
| FY 2023 | 2022-12-31 | -0.03 | 2024-03-29 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.